Soleno Therapeutics (NASDAQ:SLNO) Upgraded at Zacks Research

Zacks Research upgraded shares of Soleno Therapeutics (NASDAQ:SLNO) from a hold rating to a strong-buy rating in a report released on Monday morning,Zacks.com reports.

SLNO has been the subject of several other research reports. Wells Fargo & Company reiterated an “overweight” rating and issued a $106.00 price objective (down previously from $123.00) on shares of Soleno Therapeutics in a report on Wednesday, November 5th. Wall Street Zen upgraded Soleno Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Lifesci Capital raised Soleno Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 10th. Wolfe Research started coverage on shares of Soleno Therapeutics in a research report on Tuesday, November 18th. They set an “outperform” rating and a $75.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Soleno Therapeutics in a research report on Wednesday, October 8th. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $111.46.

Soleno Therapeutics Trading Down 3.8%

NASDAQ:SLNO opened at $44.39 on Monday. The firm has a market capitalization of $2.38 billion, a P/E ratio of -24.13 and a beta of -3.12. The company has a quick ratio of 15.88, a current ratio of 16.08 and a debt-to-equity ratio of 0.10. The company has a fifty day moving average of $49.69 and a 200 day moving average of $64.61. Soleno Therapeutics has a 52 week low of $41.50 and a 52 week high of $90.32.

Soleno Therapeutics (NASDAQ:SLNO) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.39. The firm had revenue of $66.02 million during the quarter, compared to analysts’ expectations of $47.46 million. On average, research analysts predict that Soleno Therapeutics will post -3.72 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of SLNO. JPMorgan Chase & Co. grew its holdings in Soleno Therapeutics by 52.8% in the third quarter. JPMorgan Chase & Co. now owns 407,444 shares of the company’s stock worth $27,543,000 after purchasing an additional 140,779 shares during the period. CIBC Bancorp USA Inc. bought a new stake in shares of Soleno Therapeutics in the 3rd quarter worth approximately $301,000. Danske Bank A S purchased a new stake in shares of Soleno Therapeutics in the 3rd quarter worth approximately $27,000. PharVision Advisers LLC purchased a new stake in shares of Soleno Therapeutics in the 3rd quarter worth approximately $288,000. Finally, Samlyn Capital LLC increased its position in Soleno Therapeutics by 94.1% during the 3rd quarter. Samlyn Capital LLC now owns 466,175 shares of the company’s stock valued at $31,513,000 after buying an additional 226,048 shares in the last quarter. 97.42% of the stock is currently owned by institutional investors.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.